Sage Therapeutics Announces Presentation of Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease - Yahoo Finance

CAMBRIDGE, Mass., March 15, 2022--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain...

Data Presented at the AD/PD 2022 Advances in Science & Therapy International Conference on Alzheimers and Parkinsons Diseases and Related Neurological Disorders The PARADIGM Study is a Phase 2, … [+9317 chars]

full article...